NCT03904251 2023-11-18
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
Clinical Trials
8 trialsNCT03878927 2023-03-10
CPX GO
Weill Medical College of Cornell University
Phase 1 Terminated
NCT04326439 2022-06-15
AflacLL1901 (CHOA-AML)
Emory University
Phase 2 Terminated
NCT00038805 2018-10-31
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2/3 Terminated
NCT00673153 2017-06-01
Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00660036 2016-01-15
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
University of Pittsburgh
Phase 1 Terminated
NCT00577694 2015-10-12
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00669890 2015-04-22
High Risk
New York Medical College
Phase 1 Terminated